| Literature DB >> 32321522 |
Yoji Miyahara1,2, Shida Takashi3, Yoshiaki Shimizu4, Masayuki Ohtsuka5.
Abstract
BACKGROUND: A growing body of evidence suggests that inflammatory response markers such as the neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) are associated with outcomes of various malignancies. However, no study has reported the prognostic value of NLR and LMR in patients with distal bile duct cancer (DBDC) to date. We investigated the prognostic significance of these inflammatory markers in patients with DBDC who underwent radical resection.Entities:
Keywords: Distal bile duct cancer; LMR; NLR; Prognostic maker
Year: 2020 PMID: 32321522 PMCID: PMC7178599 DOI: 10.1186/s12957-020-01847-2
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Demographic and clinicopathological features
| Variables | Total ( | |
|---|---|---|
| Age (year) | Mean ± SD | 70 (66–77) |
| Gender | Male | 33 (82%) |
| Female | 7 (18%) | |
| Differentiation | Well | 8 (20%) |
| Moderately | 30 (77%) | |
| Poorly | 2 (3%) | |
| T classification | T1 | 4 (10%) |
| T2 | 6 (15%) | |
| T3 | 29 (73%) | |
| T4 | 1 (3%) | |
| N classification | N (+) | 19 (48%) |
| N (−) | 21 (52%) | |
| Resection margin | R0 | 29 (73%) |
| R1 | 8 (20%) | |
| R2 | 3 (8%) | |
| alb (g/dL) | Mean ± SD | 3.7 (3.3–3.9) |
| CRP (mg/dL) | Mean ± SD | 0.27 (0.1–1.3) |
| CEA (ng/mL) | Mean ± SD | 2.6 (1.9–4.0) |
| CA19-9 (U/mL) | Mean ± SD | 53.9 (10.1–173.5) |
| WBC (/mm3) | Mean ± SD | 5800 (4200–7000) |
| Hb (g/dL) | Mean ± SD | 11.6 (10.5–13.1) |
| plt (104/mm3) | Mean ± SD | 22.2 (19.4–26.7) |
| NLR | Mean ± SD | 1.98 (1.37–2.54) |
| LMR | Mean ± SD | 4.75 (2.93–5.84) |
Fig. 1Receiver operating characteristic (ROC) curve analysis for 5 years survival to set cutoff values for neutrophil-to-lymphocyte ratio (NLR) and lymphocyte -to-monocyte ratio (LMR). The cutoff value for NLR and LMR were 3.14 and 4.55, respectively. The area under the curve (AUC) for NLR and LMR was 0.624 and 0.699, respectively
The collinearity of clinicopathological factors between groups that divided by NLR and LMR
| Factors | NLR | LMR | |||||
|---|---|---|---|---|---|---|---|
| NLR ≥ 3.14 | NLR < 3.14 | LMR ≥ 4.55 | LMR < 4.55 | ||||
| Age (years) | ≥ 65 | 5 | 26 | 0.503 | 19 | 12 | 0.135 |
| < 65 | 2 | 7 | 3 | 6 | |||
| Gender | Male | 6 | 27 | 0.645 | 17 | 16 | 0.297 |
| Female | 1 | 6 | 5 | 2 | |||
| Differentiation | well differentiated | 0 | 8 | 0.181 | 3 | 5 | 0.237 |
| others | 7 | 25 | 19 | 13 | |||
| T classification | T1/2 | 2 | 8 | 0.572 | 6 | 4 | 0.503 |
| T3/4 | 5 | 25 | 16 | 14 | |||
| N classification | N (−) | 4 | 17 | 0.559 | 14 | 7 | 0.203 |
| N (+) | 3 | 16 | 8 | 11 | |||
| Resection margin | R0 | 6 | 23 | 0.364 | 17 | 12 | 0.347 |
| R1 or R2 | 1 | 10 | 5 | 6 | |||
| Albumin (g/dL) | ≥ 3.5 | 1 | 23 | 17 | 7 | ||
| < 3.5 | 6 | 10 | 5 | 11 | |||
| CRP (mg/dL) | ≥ 0.5 | 4 | 12 | 0.273 | 6 | 10 | 0.068 |
| < 0.5 | 3 | 21 | 16 | 8 | |||
| CEA (ng/mL) | ≥ 2.5 | 4 | 17 | 0.559 | 12 | 9 | 0.512 |
| < 2.5 | 3 | 16 | 10 | 9 | |||
| CA19-9 (U/mL) | ≥ 60.2 | 5 | 14 | 0.164 | 7 | 12 | |
| < 60.2 | 2 | 19 | 15 | 6 | |||
Fig. 2a Kaplan-Meier estimates of overall survival (OS) based on neutrophil-to-lymphocyte ratio (NLR) for patient with distal bile duct cancer (log-rank test P < 0.001). b Kaplan-Meier estimates of OS based on lymphocyte-to-monocyte ratio (LMR) for patient with distal bile duct cancer (log-rank test P < 0.001)
Univariate and maltivariate analysis of the association between preoperative clinicopathological factors and overall survival in patients with distal bile duct cancer who underwent pancreaticoduodenectomy
| Factors | No. (%) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | Hazard ratio | 95% CI | |||||
| Age (years) | ≥ 65 | 31 (82%) | 0.508 | 0.2046–1.245 | 0.138 | |||
| < 65 | 9 (22%) | (Referent) | ||||||
| Gender | Male | 33 (87%) | 0.945 | 0.352–3.282 | 0.920 | |||
| Female | 7 (13%) | (Referent) | ||||||
| Differentiation | Well differentiated | 8 (20%) | 1.243 | 0.416–3.716 | 0.697 | |||
| Others | 32 (80%) | (Referent) | ||||||
| T classification | T1/2 | 10 (25%) | (Referent) | 0.6476–5.816 | 0.236 | |||
| T3/4 | 30 (75%) | 1.941 | ||||||
| N classification | N (−) | 21 (53%) | (Referent) | 1.078–5.772 | ||||
| N (+) | 19 (48%) | 2.495 | ||||||
| Resection margin | R0 | 29 (73%) | (Referent) | 0.9687–5.581 | ||||
| R1 or R2 | 11 (27%) | 2.325 | ||||||
| Albumin (g/dL) | ≥ 3.5 | 24 (60%) | (Referent) | 1.521–8.495 | 1.484 | 0.537–4.107 | 0.447 | |
| < 3.5 | 16 (40%) | 3.595 | ||||||
| CRP (mg/dL) | ≥ 0.5 | 16 (40%) | 1.220 | 0.5223–2.85 | 0.646 | |||
| < 0.5 | 24 (60%) | (Referent) | ||||||
| CEA (ng/mL) | ≥ 2.5 | 21 (53%) | 1.665 | 0.7226–3.838 | 0.231 | |||
| < 2.5 | 19 (48%) | (Referent) | ||||||
| CA19-9 (U/mL) | ≥ 60.2 | 19 (48%) | 3.165 | 1.345–7.449 | 2.614 | 0.978–6.993 | 0.056 | |
| < 60.2 | 21 (53%) | (Referent) | ||||||
| NLR | ≥ 3.14 | 8 (20%) | 11.810 | 3.296–42.32 | 6.133 | 1.453–25.900 | ||
| < 3.14 | 32 (80%) | (Referent) | ||||||
| LMR | ≥ 4.55 | 18 (45%) | (Referent) | 1.826–12.81 | 3.16 | 1.024–9.751 | ||
| < 4.55 | 22 (55%) | 4.837 | ||||||